Fig. 2 | Scientific Reports

Fig. 2

From: Apatinib-Induced STAT1/NK axis activation augments PD-1 inhibitor efficacy in advanced Hepatocellular Carcinoma

Fig. 2

The efficacy of apatinib in combination with PD-1 inhibitors in vitro subcutaneous tumor models for the treatment of HCC. (A) Create a model diagram for the in vitro subcutaneous tumor model for HCC. (B) Treatment cycle diagram. (C) Changes in tumor volume for each treatment group in Hepa1-6. (D) Survival rate curves for each treatment group. (E) Changes in tumor volume for each treatment group in Hep 53.4. (F) Survival rate curves for each treatment group in Hep 53.4. (G) Photos of Hepa1-6 tumor volume changes for each treatment group. (H) Western blotting to detect the expression of STAT1 protein in Hepa1-6 tumor tissue of each treatment group.

Back to article page